Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology PortfolioBusiness Wire • 08/17/22
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point TherapeuticsBusiness Wire • 08/16/22
10 defensive stocks that can also provide you with growth and dividends over the long termMarket Watch • 08/10/22
Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple MyelomaBusiness Wire • 08/10/22
Bristol Myers Squibb to Host Virtual Investor Event to Discuss ESC 2022 HighlightsBusiness Wire • 08/03/22
Famed "Big Short" Investor Loves This Multibillion-Dollar Company -- Should You?The Motley Fool • 08/03/22
These eight health-care stocks can keep you invested in the market with less worryMarket Watch • 08/02/22
Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell CarcinomaBusiness Wire • 07/29/22
Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 07/27/22
The Generics Are Here: How Bristol Myers Squibb Expects Patent Losses To Hit In 2022Investors Business Daily • 07/27/22